10,799 results match your criteria Journal of Hepatology[Journal]


Update of the statements on biology and clinical impact of occult hepatitis b virus infection.

J Hepatol 2019 Apr 17. Epub 2019 Apr 17.

Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both the existing controversial and newly emerging aspects, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.034DOI Listing

Liver-derived Cell-free Nucleic Acids in Plasma: Biology and Applications in Liquid Biopsies.

J Hepatol 2019 Apr 17. Epub 2019 Apr 17.

Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China; Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China; State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. Electronic address:

There is much global research interest into the use of cell-free DNA (cfDNA) for liquid biopsies. cfDNA-based noninvasive prenatal testing (NIPT) for fetal chromosomal aneuploidies was the first success in using cfDNA technology to profoundly transform clinical practice, and has been rapidly adopted in dozens of countries and used by millions of pregnant women every year. Prompted by such developments, efforts to use cfDNA for other fields, especially for cancer detection and monitoring have been actively pursued in recent years. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193025
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.04.003DOI Listing
April 2019
1 Read

Clinical utility of genomic analysis in adults with idiopathic liver disease.

J Hepatol 2019 Apr 12. Epub 2019 Apr 12.

Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA; Department of Pathology, Yale School of Medicine, New Haven, CT, USA. Electronic address:

Background & Aims: Adult patients suffering from liver disease of unknown cause represent an understudied and underserved population. The use of whole-exome sequencing (WES) for the assessment of a broader spectrum of non-oncological diseases, among adults, remains poorly studied. We assessed the utility of WES in the diagnosis and management of adults with unexplained liver disease despite comprehensive evaluation by a hepatologist and with no history of alcohol overuse. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193011
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.036DOI Listing
April 2019
1 Read

Individualized medicine comes to the liver clinic.

J Hepatol 2019 Apr 5. Epub 2019 Apr 5.

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193021
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.025DOI Listing
April 2019
1 Read

Learning from a clinical cohort for HCV vaccine development.

J Hepatol 2019 Apr 13. Epub 2019 Apr 13.

Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France; Université de Strasbourg, 67000 Strasbourg, France; Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Institut Universitaire de France, 75231 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193022
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.030DOI Listing
April 2019
2 Reads

Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe.

J Hepatol 2019 Apr 11. Epub 2019 Apr 11.

Department of Surgery and Cancer, Liver Unit, St Mary's Hospital NHS, Imperial College London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193014
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.008DOI Listing
April 2019
1 Read

Extracellular vesicles, the liquid biopsy of the future.

J Hepatol 2019 Apr 12. Epub 2019 Apr 12.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193007
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.030DOI Listing
April 2019
1 Read

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

J Hepatol 2019 May 27;70(5):1008-1015. Epub 2018 Dec 27.

Department of Gastroenterology and Hepatology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.022DOI Listing

Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.

J Hepatol 2019 Apr 10. Epub 2019 Apr 10.

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:

Background And Aims: The clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) remains subject to debate as definitive randomized controlled trials are lacking. We aimed to determine whether UDCA prolongs transplantation (LT) free survival in PBC.

Methods: This international cohort study included patients from the Global PBC Study Group database, originating from 8 countries in Europe and North America. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.04.001DOI Listing
April 2019
1 Read

Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?

J Hepatol 2019 Apr 10. Epub 2019 Apr 10.

MRC Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193018
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.015DOI Listing
April 2019
3 Reads

EASL International Recognition Award Recipient 2019: Prof. Flair José Carrilho.

Authors:
Vicente Arroyo

J Hepatol 2019 May;70(5):826-827

European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183264
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.12.024DOI Listing
May 2019
2 Reads

EASL Recognition Award Recipient 2019: Prof. Vincenzo Mazzaferro.

J Hepatol 2019 May;70(5):824-825

Department of Surgery, Regional Hospital of Lugano, Lugano, Switzerland; Transplantation Unit, University Hospitals of Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.014DOI Listing
May 2019
1 Read

EASL Recognition Award Recipient 2019: Prof. Deirdre Kelly.

Authors:
Ulrich Baumann

J Hepatol 2019 May;70(5):822-823

Paediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.002DOI Listing

Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.

J Hepatol 2019 Apr 6. Epub 2019 Apr 6.

Department of Biomedical Sciences of Cells and Systems, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address:

Background & Aims: Hepatocyte polarity is essential for the development of bile canaliculi and transport of bile and waste products such as copper safely out of the liver. Genetically inherited defects in polarized processes can cause severe diseases. Functional studies of autologous mutated proteins in the context of the polarized hepatocyte have been challenging because of the lack of appropriate cell models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.031DOI Listing
April 2019
1 Read

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies.

J Hepatol 2019 Apr 6. Epub 2019 Apr 6.

Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.

Background And Aims: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study.

Methods: We included all HIV-infected adults with a positive hepatitis B surface antigen followed in one of four prospective European cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.032DOI Listing
April 2019
2 Reads

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

J Hepatol 2019 Apr 6. Epub 2019 Apr 6.

UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom; Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, United Kingdom. Electronic address:

Background & Aims: We aimed to develop and evaluate a pathway for management of patients with non-alcoholic fatty liver disease (NAFLD) using blood tests to stratify patients in primary care to improve detection of cases of advanced fibrosis and cirrhosis, and avoid unnecessary referrals to secondary care.

Methods: This was a prospective longitudinal cohort study with before-and-after analysis and comparison to unexposed controls. We used a two-step algorithm combining the use of FIB-4 followed by the ELF test if required RESULTS: In total, 3,012 patients were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.033DOI Listing
April 2019
1 Read

Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

J Hepatol 2019 Apr 5. Epub 2019 Apr 5.

Section of Gastroenterology and Hepatology, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, Italy. Electronic address:

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.027DOI Listing
April 2019
1 Read

A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea.

J Hepatol 2019 Apr 5. Epub 2019 Apr 5.

Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea. Electronic address:

Background & Aims: Which antiviral agent between entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) is superior in improving prognosis for chronic hepatitis B (CHB) is unclear. Here, we assessed the ability of these two antivirals to prevent liver-disease progression in treatment-naïve CHB patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.028DOI Listing

Inherited nonalcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations.

J Hepatol 2019 Apr 4. Epub 2019 Apr 4.

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

Background And Aims: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition and the most common liver disease worldwide, affecting more than one-third of the population. So far there has been no disclosure of the mendelian inheritance in NAFLD families.

Methods: We performed whole-exome or targeted next-generation sequencing on autosomal dominant NAFLD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.026DOI Listing
April 2019
11.336 Impact Factor

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.

J Hepatol 2019 Apr 3. Epub 2019 Apr 3.

de Duve Institute, Université catholique de Louvain, Brussels, Belgium. Electronic address:

Background And Aims: Alterations of individual genes variably affect development of hepatocellular carcinoma (HCC), prompting the need to characterise the function of tumor-promoting genes in the context of gene regulatory networks (GRN).

Methods: Using data from The Cancer Genome Atlas, from the LIRI-JP (Liver Cancer - RIKEN, JP project), and from our transcriptomic, transfection and mouse transgenic experiments, we identify a GRN which functionally links LIN28B-dependent dedifferentiation with dysfunction of β-CATENIN (CTNNB1). We further generated and validated with human cell lines and in vivo expression data a quantitative mathematical model of the GRN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.024DOI Listing

Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.

J Hepatol 2019 Apr 1. Epub 2019 Apr 1.

Division of HIV/AIDS, STI and Viral Hepatitis, Rwanda Biomedical Center, Kigali, Rwanda.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.011DOI Listing
April 2019
1 Read

Progression-free survival: Starting point or endpoint in advanced HCC trial design?

Authors:
Richard S Finn

J Hepatol 2019 Mar 31. Epub 2019 Mar 31.

Department of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193013
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.002DOI Listing
March 2019
4 Reads

Trial endpoints for systemic therapy in patients with hepatocellular carcinoma.

J Hepatol 2019 Mar 11. Epub 2019 Mar 11.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193013
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.001DOI Listing
March 2019
3 Reads

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

J Hepatol 2019 Mar 31. Epub 2019 Mar 31.

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Around half of patients with HCC will receive systemic therapies during their life span. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal antitumoral efficacy, toxicity, or trials with a lack of enrichment strategies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193007
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.028DOI Listing
March 2019
4 Reads

Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.

J Hepatol 2019 Mar 29. Epub 2019 Mar 29.

Amsterdam University Medical Centers, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Meibergdreef 9, Amsterdam, The Netherlands. Electronic address:

Background: Progressive familial intrahepatic cholestasis type 3 (PFIC3) often leads to end-stage liver disease before adulthood with limited therapeutic options, due to impaired ABCB4 dependent phospholipid transport to bile. To restore ABCB4 function we propose adeno-associated virus serotype 8 (AAV8)-mediated gene therapy directed to the liver, although achieving stable transgene expression in hyperproliferative tissue is challenging. By restoring the phospholipid content in bile to levels that prevent liver damage, this study aims for stable hepatic ABCB4 expression and long-term correction of the phenotype in a murine model of PFIC3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.021DOI Listing

The Circadian Clock and Liver Function in Health and Disease.

J Hepatol 2019 Mar 28. Epub 2019 Mar 28.

Institut de Recherche sur les Maladies Virales et Hépatiques INSERM, UMR 1110, Université de Strasbourg Strasbourg, France; Pôle Hépato-Digestif, Institut Hospitalo-Universitaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Electronic address:

All organisms are subjected each day to changes in the light intensity generated by the Earth's rotation around its own axis. To anticipate this geo-physical variability, and to appropriately respond biochemically, most species, including mammals, have evolved an approximate 24-hour endogenous timing mechanism known as the circadian clock (CC). The 'clock' is self-sustained, cell autonomous and present in every cell type. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193019
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.020DOI Listing
March 2019
3 Reads

Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.

J Hepatol 2019 Mar 28. Epub 2019 Mar 28.

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:

Background And Aims: The immunogenomic characteristics of hepatocellular carcinomas (HCCs) with immune cell stroma (HCC-IS) histologically defined have not been clarified. We investigated the clinical and molecular features of HCC-IS and the prognostic potential of Epstein-Barr virus (EBV) infection.

Methods: We evaluated 219 patients with conventional HCC (C-HCC) and 47 with HCC-IS using in situ hybridization for EBV, immunohistochemistry, multiplex immunofluorescence staining, and whole exome and transcriptome sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.018DOI Listing

The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.

J Hepatol 2019 Mar 23. Epub 2019 Mar 23.

Regional Centre for Imported and Tropical Diseases, Oslo University Hospital, Ullevål, Oslo, Norway; Department of Infectious Diseases, Vestfold Hospital Trust, Tønsberg, Norway. Electronic address:

Background & Aims: In 2015, the World Health Organization (WHO) issued guidelines for the management of chronic hepatitis B (CHB) in low- and middle-income countries, but little is known about the applicability of the WHO treatment criteria in sub-Saharan Africa. The aim of this study was to evaluate the diagnostic performance of the WHO guidelines in a large CHB cohort in Ethiopia.

Methods: Treatment-naïve adults who attended a public CHB clinic in Addis Ababa were included in this analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.037DOI Listing
March 2019
1 Read
11.336 Impact Factor

EASL Clinical Practice Guidelines: Drug-induced liver injury.

Authors:

J Hepatol 2019 Mar 27. Epub 2019 Mar 27.

Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.014DOI Listing
March 2019
1 Read

Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.

J Hepatol 2019 Mar 23. Epub 2019 Mar 23.

Institute of Digestive Disease and The Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong. Electronic address:

Background & Aims: p38 mitogen-activated protein kinases are important inflammatory factors. p38α alteration has been implicated in both human and mouse inflammatory disease models. We characterized the cell type-specific role of p38α in non-alcoholic steatohepatitis (NASH). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193018
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.03.014DOI Listing
March 2019
11 Reads

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.

J Hepatol 2019 Mar 22. Epub 2019 Mar 22.

Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.

Background And Aims: Intrahepatic (ICC) and extrahepatic cholangiocarcinoma (ECC) have been rarely studied distinctively, probably due to difficulties in their diagnosis and certification. Mortality trends from these two neoplasms have been inconsistent over the last decades. The aim of this study is to analyze trends in mortality from ICC and ECC in selected countries worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.013DOI Listing
March 2019
1 Read

KLRG1+ natural killer cells exert a novel anti-fibrotic function in chronic hepatitis B.

J Hepatol 2019 Mar 21. Epub 2019 Mar 21.

Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; Blacktown Clinical School, Western Sydney University, Blacktown, NSW 2148; Blacktown Hospital, Blacktown, NSW 2148, Australia. Electronic address:

Background & Aims: Natural killer (NK) cells are known to exert strong antiviral activity. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is expressed by terminally differentiated NK cells and KLRG1-expressing lymphocytes are known to expand following chronic viral infections. The role of KLRG1 in pathogenesis of chronic hepatitis B (CHB) remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.012DOI Listing
March 2019
1 Read

Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.

J Hepatol 2019 Mar 15. Epub 2019 Mar 15.

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address:

Background & Aims: Congenital hepatic fibrosis (CHF) is a genetic liver disease with abnormal proliferation of cholangiocyte and progressive hepatic fibrosis. Mutation of polycystic kidney and hepatic disease 1 (PKHD1) causes CHF and the dysfunction of its coding protein, fibrocystin, is associated with ductal plate malformation during fetal development and further pathological changes in CHF patients. However, the underlying molecular mechanism of CHF remains unclear, which is quite different from liver cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.024DOI Listing
March 2019
8 Reads

Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.

J Hepatol 2019 Mar 15. Epub 2019 Mar 15.

Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. Electronic address:

Background & Aims: Hepatitis C virus (HCV) is a major cause of chronic liver disease, infecting approximately 71 million people worldwide. Assembly of infectious HCV particles involves host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2. Many of these host cell proteins are common markers of exosomes, most notably the intracellular adaptor protein syntenin required exosome biogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.006DOI Listing
March 2019
3 Reads
11.336 Impact Factor

A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.

J Hepatol 2019 Mar 14. Epub 2019 Mar 14.

Gene Therapy Laboratory, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET, Universidad Austral, Derqui-Pilar, Argentina; Liver Unit, Hospital Universitario Austral, Derqui-Pilar, Argentina. Electronic address:

Background And Aims: A causal link has recently been established between epigenetic alterations and hepatocarcinogenesis, indicating that epigenetic inhibition may have therapeutic potential. We aimed to identify and target epigenetic modifiers that show molecular alterations in hepatocellular carcinoma (HCC).

Methods: We studied the molecular-clinical correlations of epigenetic modifiers including bromodomains, histone acetyltransferases, lysine methyltransferases and lysine demethylases in HCC using the Cancer Genome Atlas (TCGA) data of 365 HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.007DOI Listing

Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.

J Hepatol 2019 May 14;70(5):831-838. Epub 2019 Mar 14.

CHRU de Lille, France, Service des maladies de l'appareil digestif, Université Lille 2 and Inserm U795, France. Electronic address:

Background & Aims: Before antiviral therapy, kidney transplant recipients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) had poor outcomes. Since the 90s, nucleos(t)ide analogues have been widely used in HBV-infected patients, while interferon-based therapy was rarely used in HCV-infected patients. The aim of this study was to assess the impact of HBV and HCV on patient and graft survival, according to viral replication status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.036DOI Listing
May 2019
4 Reads

F-actin dynamics regulates mammalian organ growth and cell fate maintenance.

J Hepatol 2019 Mar 14. Epub 2019 Mar 14.

Department of Molecular Medicine DMM, University of Padova, Italy. Electronic address:

Background & Aims: In vitro, several data indicate that cell function can be regulated by the mechanical properties of cells and of the microenvironment. Cells measure these features by developing forces via their actomyosin cytoskeleton, and respond accordingly by transducing forces into biochemical signals that instruct cell behavior. Among these, the transcriptional coactivators YAP/TAZ recently emerged as key factors mediating multiple responses to actomyosin contractility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.022DOI Listing
March 2019
4 Reads

Hepatovirus 3ABC proteases and evolution of mitochondrial antiviral signaling protein (MAVS).

J Hepatol 2019 Mar 13. Epub 2019 Mar 13.

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address:

Background & Aims: Unlike other hepatitis viruses that have infected primates for millions of years, hepatitis A virus (HAV) likely entered human populations only 10-12 thousand years ago after jumping from a rodent host. The phylogeny of modern hepatoviruses that infect rodents and bats suggest that multiple similar host shifts have occurred in the past. The factors determining such shifts are unknown, but the capacity to overcome innate antiviral responses in a foreign species is likely key. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.020DOI Listing
March 2019
3 Reads

Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.

J Hepatol 2019 Mar 13. Epub 2019 Mar 13.

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:

Background & Aims: Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal in patients receiving up to 144 weeks of TDF monotherapy. We aimed to assess the efficacy and safety of TDF monotherapy given for up to 240 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.021DOI Listing

Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.

J Hepatol 2019 Mar 13. Epub 2019 Mar 13.

Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address:

Background & Aims: Microvascular invasion (MVI) impairs surgical outcomes in patients with hepatocellular carcinoma (HCC). As there is no single highly reliable factor to preoperatively predict MVI, we developed a computational approach integrating large-scale clinical and imaging modalities, especially radiomic features from contrast-enhanced CT, to predict MVI and clinical outcomes in patients with HCC.

Methods: In total, 495 surgically resected patients were retrospectively included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.023DOI Listing
March 2019
11.336 Impact Factor

Prognostic markers at adolescence in patients requiring liver transplantation for biliary atresia in adulthood.

J Hepatol 2019 Mar 13. Epub 2019 Mar 13.

Paediatric Liver, GI and Nutrition Centre and Mowatlabs, Kings College Hospital, London, UK.

Background & Aims: In patients with biliary atresia (BA), the rate of native liver survival (NLS) to adulthood has been reported as 14-44% worldwide. Complications related to portal hypertension (PHT) and cholangitis are common in adulthood. For those requiring liver transplantation (LT), the timing can be challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.005DOI Listing
March 2019
2 Reads

Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.

J Hepatol 2019 Mar 12. Epub 2019 Mar 12.

Department of Surgery, The University of Hong Kong, Hong Kong; Department of Surgery, Queen Mary Hospital, Hong Kong; Department of Surgery, The University of Hong Kong-Shenzhen Hospital, China.

Background & Aims: The impact of hepatitis B core antibody (anti-HBc) positive liver grafts on survival and the risk of de novo hepatitis B virus (HBV) infection after liver transplantation (LT) remain controversial. Therefore, we aimed to analyze this risk and the associated outcomes in a large cohort of patients.

Methods: This was a retrospective study that included all adults who underwent LT at Queen Mary Hospital, Hong Kong, between 2000 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.003DOI Listing
March 2019
11.336 Impact Factor

Global Liver Disease Burdens and Research Trends: Analysis from a China Perspective.

J Hepatol 2019 Mar 11. Epub 2019 Mar 11.

Department of Health Sciences, National Natural Science Foundation of China, Beijing, China. Electronic address:

Liver diseases affect millions of people worldwide. In most developed countries, the incidence of viral hepatitis is waning as a result of modern advances in disease prevention, diagnosis, and therapies. Expanded programs for systematic immunization against hepatitis B virus (HBV) have also significantly brought down the number of new cases in many countries, including China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.004DOI Listing
March 2019
3 Reads
11.336 Impact Factor

Digital pathology, what is the future?

Authors:
V Paradis A Quaglia

J Hepatol 2019 May 8;70(5):1016-1018. Epub 2019 Mar 8.

Institute of Liver Studies, King's College Hospital, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.03.023DOI Listing

Mortality of acute-on-chronic liver failure: What is the role of obesity?

Authors:
Vinay Sundaram

J Hepatol 2019 Mar 8. Epub 2019 Mar 8.

Division of Gastroenterology and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.018DOI Listing
March 2019
1 Read

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.

J Hepatol 2019 Mar 8. Epub 2019 Mar 8.

Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain.

Background & Aims: People who inject drugs (PWID) and are on opioid agonist therapy (OAT) might have lower adherence to direct-acting antivirals (DAAs) against hepatitis C virus (HCV) and, therefore, lower rates of sustained virologic response (SVR). Because of this, we compared the SVR rates to interferon-free DAA combinations in individuals receiving OAT and those not receiving OAT in a real-world setting.

Methods: The HEPAVIR-DAA cohort, recruiting HIV/HCV-coinfected patients (NCT02057003), and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are ongoing prospective multicenter cohorts of patients receiving DAAs in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.02.018DOI Listing
March 2019
1 Read